Metabolic syndrome in peritoneal dialysis patients

NDT Plus

Volumn 1, Issue 4, 2008, Pages 206-214

  Li, Philip Kam Tao ^a   Kwan, Bonnie Ching Ha ^a   Szeto, Cheuk Chun ^a   Ko, Gary Tin Choi ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Metabolic syndrome; Obesity; Peritoneal dialysis

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICODEXTRIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

BODY MASS; CHOLESTEROL BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 48849087994     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn073     Document Type: Review

References (95)

1. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
3. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
5. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus WHO/NCD/NCS/ 99.2. Geneva, 1999.
6. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443
7. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
8. Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 2005; 28: 2289-2304
9. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002Washington, DC. Diabetes Care 2003; 26: 1297-1303
10. Zimmet P, Magliano D, Matsuzawa Y et al. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295-300
11. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14(Suppl 5): 242S-249S
12. Hutley L, Prins JB. Fat as an endocrine organ: Relationship to the metabolic syndrome. Am J Med Sci 2005; 330: 280-289
13. Trayhurn P, Wood IS. Signalling role of adipose tissue: Adipokines and inflammation in obesity. Biochem Soc Trans 2005; 33(Pt 5): 1078-1081
14. Bastard JP, Jardel C, Delattre J et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 1999; 99: 2221-2222
15. Bhagat K, Vallance P. Inflammatory cytokines impair endotheliumdependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047
16. Hotamisligil GS, Peraldi P, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668
17. Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674
18. Quehenberger P, Exner M, Sunder-Plassmann R et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002; 90: 711-718
19. Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/ EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 1991; 266: 21839-21845
20. Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740
21. von Eynatten M, Schneider JG, Humpert PM et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: An association independent of systemic inflammation and insulin resistance. Diabetes Care 2004; 27: 2925-2929
22. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119
23. Whitehead JP, Richards AA, Hickman IJ et al. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280
24. Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-809
25. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428
26. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006; 6: 177-181
27. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: A meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 1998; 22: 1164-1171
28. World Health Organization, Physical Status. The use and interpretation of anthropometry. Technical Report Series 854, Geneva, 1995.
29. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO Expert Consultation on Obesity, Geneva, 3-5 June 1997. WHO/NUT/NCT/98.1. Technical Report Series Number 894, Geneva, 2000.
30. Deurenberg-Yap M, Chew SK, Deurenberg P. Elevated body fat percentage and cardiovascular risks at low body mass index levels among Singaporean Chinese, Malays and Indians. Obes Rev 2002; 3: 209-215
31. Ko GT, Chan JC, Cockram CS et al. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. Int J Obes Relat Metab Disord 1999; 23: 1136-1142
32. World Health Organisation, International Association for the Study of Obesity, International Obesity TaskForce. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications, 2000
33. Kanazawa M, Yoshiike N, Osaka T et al. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac J Clin Nutr 2002; 11(Suppl 8): S732-S737
34. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults-study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002; 15: 83-96
35. Ko GT, Tang J, Chan JC et al. Lower BMI cut-off value to define obesity in Hong Kong Chinese: An analysis based on body fat assessment by bioelectrical impedance. Br J Nutr 2001; 85: 239-242
36. Yajnik CS, Yudkin JS. The Y-Y paradox. Lancet 2004; 363: 163
37. Ko GT, Tang JS. Waist circumference and BMI cut-off based on 10-year cardiovascular risk: Evidence for 'central pre-obesity'. Obesity (Silver Spring) 2007; 15: 2832-2839
38. Ferland M, Despres JP, Tremblay A et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989; 61: 139-148
39. Koester RS, Hunter GR, Snyder S et al. Estimation of computerized tomography derived abdominal fat distribution. Int J Obes Relat Metab Disord 1992; 16: 543-554
40. Pouliot MC, Despres JP, Lemieux S et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460-468
41. Eston RG, Fu F, Fung L. Validity of conventional anthropometric techniques for predicting body composition in healthy Chinese adults. Br J Sp Med 1995; 29: 52-56
42. De Waart FG, Li R, Deurenberg P. Comparison of body composition assessments by bioelectrical impedance and by anthropometry in premenopausal Chinese women. Br J Nutr 1993; 69: 657-664
43. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167
44. Szeto CC, Chow KM, Kwan BC et al. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis. Am J Kidney Dis 2007; 49: 524-532
45. de Simone G, Devereux RB, Chinali M et al. Strong Heart Study Investigators. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: The strong heart study. Diabetes Care 2007; 30: 1851-1856
46. Athyros VG, Ganotakis ES, Elisaf MS et al. GREECE-METS Collaborative Group. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007; 117: 204-210
47. Sandhofer A, Iglseder B, Paulweber B et al. Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest 2007; 37: 109-116
48. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National health and nutrition examination survey. JAMA 2002; 287: 356-359
49. Thomas GN, Ho SY, Janus ED et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 2005; 67: 251-257
50. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
51. Ko GT, SoWY, Chan NN et al. Prediction of cardiovascular and total mortality in Chinese type 2 diabetic patients by the WHO definition for the metabolic syndrome. Diabetes Obes Metab 2006; 8: 94-104
52. Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 2005; 18(Pt 2): 100S-105S
53. Tanaka H, Shiohira Y, Uezu Y et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69: 369-374
54. Chen J, Gu D, Chen CS et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 2007; 22: 1100-1106
55. Johnson DW, Armstrong K, Campbell SB et al. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factormodification. Nephrology (Carlton) 2007; 12: 391-398
56. Young DO, Lund RJ, Haynatzki G et al. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int 2007; 11: 86-95
57. Yudkin JS, Kumari M, Humphries SE et al. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214
58. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112-S119
59. Li PK, Chow KM. The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. Perit Dial Int 2005; 25(Suppl 3): S80-S83
60. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459
61. Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763-778
62. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638
63. Hu FB, Willett WC, Li T et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351: 2694-2703
64. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979; 32: 563-576
65. Stevens J, Cai J, Evenson KR et al. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol 2002; 156: 832-841
66. Stevens J, Plankey MW, Williamson DF et al. The body mass indexmortality relationship in white and African American women. Obes Res 1998; 6: 268-277
67. Johansen KL, Young B, Kaysen GA et al. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80: 324-332
68. Snyder JJ, Foley RN, Gilbertson DT et al. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int 2003; 64: 1838-1844
69. Szeto CC,Wong TY, Leung CB et al. Importance of dialysis adequacy in mortality andmorbidity of chinese CAPD patients. Kidney Int 2000; 58: 400-407
70. Wong JS, Port FK, Hulbert-Shearon TE et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int 1999; 55: 2515-2523
71. Abbott KC, Glanton CW, Trespalacios FC et al. Body mass index, dialysis modality, and survival: Analysis of the United States renal data system dialysis morbidity and mortality wave II study. Kidney Int 2004; 65: 597-605
72. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among 'large' ESRD patients in the United States. Kidney Int 2004; 65: 2398-2408
73. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 2003; 14: 2894-2901
74. McDonald SP, Collins JF, Rumpsfeld M et al. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 2004; 24: 340-346
75. Johnson DW, Mudge DW, Sturtevant JM et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23: 276-283
76. Ramkumar N, Pappas LM, Beddhu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25: 461-469
77. Stompor T, Sulowicz W, Dembinska-Kiec A et al. An association between body mass index and markers of inflammation: Is obesity the proinflammatory state in patients on peritoneal dialysis? Perit Dial Int 2003; 23: 79-83
78. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2): S37-S41
79. Szeto CC, Chow KM, Leung CB et al. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrol Dial Transplant 2007; 22: 1697-1702
80. Lameire N, Matthys D, Matthys E et al. Effects of long-termCAPD on carbohydrate and lipid metabolism. Clin Nephrol 1988; 30(Suppl 1): S53-S58
81. Kurtz SB, Wong VH, Anderson CF et al. Continuous ambulatory peritoneal dialysis. Three years' experience at the Mayo clinic. Mayo Clin Proc 1983; 58: 633-639
82. Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The diabetes prevention program randomized trial. Ann Intern Med 2005; 142: 611-619
83. Martens FM, Visseren FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-1480
84. Wong TY, Szeto CC, Chow KM et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46: 713-719
85. Marshall J, Jennings P, Scott A et al. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64: 1480-1486
86. Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint National committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572
87. Li PK, Chow KM, Wong TY et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139: 105-112
88. Despres JP, Lemieux I, Prud' homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-720
89. Axelsson J, Rashid Qureshi A, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222-1229
90. Axelsson J, Møoller HJ, Witasp A et al. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 2006; 48: 916-925
91. Hollis J, Corden E, Williams PF. Longitudinal evaluation of a weight reduction program for patients on peritoneal dialysis. Perit Dial Int 2005; 25(Suppl 3): S152-S154
92. Rucker D, Padwal R, Li SK et al. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 2007; 335: 1194-1199
93. Wolfson M, Piraino B, Hamburger RJ et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40: 1055-1065
94. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
95. Isbel NM, Haluska B, Johnson DW et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 2006; 151: 745-753